Enovis Corporation
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 1.43B | 1.56B | 1.71B | 2.11B | 2.25B | 6.7% | |
| Cost of Revenue | (648.51M) | (693.72M) | (716.42M) | (926.87M) | (902.79M) | -2.6% | |
Gross Profit | 777.67M | 869.38M | 990.78M | 1.18B | 1.35B | 13.9% | |
| Operating Expenses | |||||||
| Research & Development | (49.09M) | (60.83M) | (75.33M) | (91.30M) | (120.33M) | 31.8% | |
| Selling, General & Administrative | (665.77M) | (772.91M) | (830.30M) | (939.36M) | (1.07B) | 13.9% | |
| Depreciation & Amortization | (262.92M) | (219.71M) | (217.11M) | (284.80M) | (294.38M) | 3.4% | |
Operating Income (EBIT) | -62.80M | -71.18M | -65.71M | -775.72M | -18.87M | -97.6% | |
| Non-Operating Items | |||||||
| Interest Income | — | 200.00K | — | — | — | — | |
| Interest Expense | (29.11M) | (24.95M) | (19.75M) | (57.10M) | (34.82M) | -39.0% | |
| Other Income/Expenses (Net) | -58.98M | 69.11M | -1.42M | -47.20M | -1.14B | 2316.2% | |
Income Before Tax | -121.78M | -2.07M | -67.13M | -822.92M | -1.16B | 40.9% | |
| Income Tax Expense | (19.53M) | (36.12M) | (13.29M) | (4.49M) | (22.29M) | 396.3% | |
Net Income | 71.66M | -13.29M | -33.26M | -825.49M | -1.18B | 43.5% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $-2 | $-0 | $-1 | $-15 | $-21 | 39.7% | |
| Weighted Avg Shares Outstanding | 51.14M | 54.07M | 54.49M | 55.28M | 56.79M | 2.7% | |
| Weighted Avg Shares Outstanding (Diluted) | 51.14M | 54.07M | 54.49M | 55.28M | 56.79M | 2.7% | |
EBITDA | 170.25M | 241.69M | 169.73M | -481.03M | -830.22M | 72.6% |
Explore ENOV
ENOV in the Healthcare
Small Cap